Mezzion Pharma메지온

Mezzion Pharma is a loss-making drug developer whose shares have fallen sharply over the past year, with no recent news headlines in the data.

Mezzion Pharma, a Korean drug developer focused on its lead candidate udenafil, reported trailing twelve-month revenue of ₩8.4B against an operating loss of ₩18.8B for the period to H1 2026. Its share price closed at ₩52,600 on 2026-10-28, down 33.2% over one month and 13.6% over one year, and sits far below its 52-week high of ₩179,900. The company's current revenue comes from a domestic animal feed business, according to its profile.

What stands out

• Revenue has been shrinking: 2024 revenue was ₩8.6B, falling 72.9% from the prior year, and 2025 revenue fell a further 8.2% to ₩7.9B.
• Losses are large relative to sales: trailing operating margin is -223.1% and net margin is -325%, and 2025 net loss was ₩34.9B.
• Free cash flow was -₩20.7B on a trailing basis, against cash of ₩40.3B and borrowings of ₩15.6B.
• Valuation metrics are not meaningful for a loss-making company: P/E is unavailable, while P/B is 41.6 and P/S is 192.7 against peers with P/E ratios of roughly 15 to 80.
• Foreign ownership fell from 25.4% to 23% over roughly 60 days, and the last 20 days saw net foreign and institutional selling with net retail buying.

What to watch

• The next half-year or annual results, to see whether revenue and operating losses improve from the trailing figures.
• Ongoing insider shareholding and 5%+ holding reports filed in October 2026, which the data does not explain in detail.
• Cash runway: the data shows ₩40.3B in cash against negative free cash flow, but does not include any financing or pipeline timeline.